Guangzhou Innogen Pharmaceutical Group Initiates Phase III Clinical Trial of Efsubaglutide Alfa for Obesity Treatment in China

Reuters

Sep 30

Guangzhou Innogen Pharmaceutical Group Initiates Phase III Clinical Trial of Efsubaglutide Alfa for Obesity Treatment in China

Guangzhou Innogen Pharmaceutical Group Co., Ltd. has announced a business update regarding its core product, Efsubaglutide Alfa, for the treatment of obesity and being overweight in the People's Republic of China. The company recently completed the first patient dosing in its Phase III clinical trial, which began in March 2025. Approximately 800 participants are expected to be enrolled in the study. Results from the clinical trial have not yet been presented, and the company has not provided a timeline for the release of future data. Guangzhou Innogen cautioned that there is no guarantee of successful development or commercialization of the product.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571631033"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571631033\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571631033?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 17:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571631033","market":"fut","top_or_hot":-1,"title":"Guangzhou Innogen Pharmaceutical Group Initiates Phase III Clinical Trial of Efsubaglutide Alfa for Obesity Treatment in China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guangzhou Innogen Pharmaceutical Group Initiates Phase III Clinical Trial of Efsubaglutide Alfa for Obesity Treatment in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Guangzhou Innogen Pharmaceutical Group Co., Ltd. has announced a business update regarding its core product, Efsubaglutide Alfa, for the treatment of obesity and being overweight in the People's Republic of China. The company recently completed the first patient dosing in its Phase III clinical trial, which began in March 2025. Approximately 800 participants are expected to be enrolled in the study. Results from the clinical trial have not yet been presented, and the company has not provided a timeline for the release of future data. Guangzhou Innogen cautioned that there is no guarantee of successful development or commercialization of the product.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Guangzhou Innogen Pharmaceutical Group Initiates Phase III Clinical Trial of Efsubaglutide Alfa for Obesity Treatment in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGuangzhou Innogen Pharmaceutical Group Initiates Phase III Clinical Trial of Efsubaglutide Alfa for Obesity Treatment in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 17:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Guangzhou Innogen Pharmaceutical Group Initiates Phase III Clinical Trial of Efsubaglutide Alfa for Obesity Treatment in China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Guangzhou Innogen Pharmaceutical Group Co., Ltd. has announced a business update regarding its core product, Efsubaglutide Alfa, for the treatment of obesity and being overweight in the People's Republic of China. The company recently completed the first patient dosing in its Phase III clinical trial, which began in March 2025. Approximately 800 participants are expected to be enrolled in the study. Results from the clinical trial have not yet been presented, and the company has not provided a timeline for the release of future data. Guangzhou Innogen cautioned that there is no guarantee of successful development or commercialization of the product.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250930:nNDL7NckzL:1","article_id":"2571631033","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571631033","pubTimestamp":1759223253,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Guangzhou Innogen Pharmaceutical Group Initiates Phase III Clinical Trial of Efsubaglutide Alfa for Obesity Treatment in China. Guangzhou Innogen Pharmaceutical Group Co., Ltd. has announced a business update regarding its core product, Efsubaglutide Alfa, for the treatment of obesity and being overweight in the People's Republic of China. The company recently completed the first patient dosing in its Phase III clinical trial, which began in March 2025. Approximately 800 participants are expected to be enrolled in the study. Results from the clinical trial have not yet been presented, and the company has not provided a timeline for the release of future data. Guangzhou Innogen cautioned that there is no guarantee of successful development or commercialization of the product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02591":"银诺医药－Ｂ"},"translate_title":"广州英诺药业集团在中国启动Efsubaglutide Alfa治疗肥胖症的III期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":0.9},"content_text":"Guangzhou Innogen Pharmaceutical Group Initiates Phase III Clinical Trial of Efsubaglutide Alfa for Obesity Treatment in China\n    \n\n        Guangzhou Innogen Pharmaceutical Group Co., Ltd. has announced a business update regarding its core product, Efsubaglutide Alfa, for the treatment of obesity and being overweight in the People's Republic of China. The company recently completed the first patient dosing in its Phase III clinical trial, which began in March 2025. Approximately 800 participants are expected to be enrolled in the study. Results from the clinical trial have not yet been presented, and the company has not provided a timeline for the release of future data. Guangzhou Innogen cautioned that there is no guarantee of successful development or commercialization of the product.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on September 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}